246 related articles for article (PubMed ID: 35853457)
1. Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma.
Ferguson ID; Lin YT; Lam C; Shao H; Tharp KM; Hale M; Kasap C; Mariano MC; Kishishita A; Patiño Escobar B; Mandal K; Steri V; Wang D; Phojanakong P; Tuomivaara ST; Hann B; Driessen C; Van Ness B; Gestwicki JE; Wiita AP
Cell Chem Biol; 2022 Aug; 29(8):1288-1302.e7. PubMed ID: 35853457
[TBL] [Abstract][Full Text] [Related]
2. Multiple myeloma cells are exceptionally sensitive to heat shock, which overwhelms their proteostasis network and induces apoptosis.
Sha Z; Goldberg AL
Proc Natl Acad Sci U S A; 2020 Sep; 117(35):21588-21597. PubMed ID: 32817432
[TBL] [Abstract][Full Text] [Related]
3. A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells.
Milan E; Perini T; Resnati M; Orfanelli U; Oliva L; Raimondi A; Cascio P; Bachi A; Marcatti M; Ciceri F; Cenci S
Autophagy; 2015; 11(7):1161-78. PubMed ID: 26043024
[TBL] [Abstract][Full Text] [Related]
4. The molecular network of the proteasome machinery inhibition response is orchestrated by HSP70, revealing vulnerabilities in cancer cells.
Oroń M; Grochowski M; Jaiswar A; Legierska J; Jastrzębski K; Nowak-Niezgoda M; Kołos M; Kaźmierczak W; Olesiński T; Lenarcik M; Cybulska M; Mikula M; Żylicz A; Miączyńska M; Zettl K; Wiśniewski JR; Walerych D
Cell Rep; 2022 Sep; 40(13):111428. PubMed ID: 36170818
[TBL] [Abstract][Full Text] [Related]
5. Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors.
Jones RJ; Singh RK; Shirazi F; Wan J; Wang H; Wang X; Ha MJ; Baljevic M; Kuiatse I; Davis RE; Orlowski RZ
Front Immunol; 2020; 11():1816. PubMed ID: 32903557
[TBL] [Abstract][Full Text] [Related]
6. Lessons Learned from Proteasome Inhibitors, the Paradigm for Targeting Protein Homeostasis in Cancer.
Kambhampati S; Wiita AP
Adv Exp Med Biol; 2020; 1243():147-162. PubMed ID: 32297217
[TBL] [Abstract][Full Text] [Related]
7. Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib.
Neznanov N; Komarov AP; Neznanova L; Stanhope-Baker P; Gudkov AV
Oncotarget; 2011 Mar; 2(3):209-21. PubMed ID: 21444945
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of the HSP70 inhibitor PET-16 in multiple myeloma.
Bailey CK; Budina-Kolomets A; Murphy ME; Nefedova Y
Cancer Biol Ther; 2015; 16(9):1422-6. PubMed ID: 26176532
[TBL] [Abstract][Full Text] [Related]
9. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
Brünnert D; Kraus M; Stühmer T; Kirner S; Heiden R; Goyal P; Driessen C; Bargou RC; Chatterjee M
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1666-1676. PubMed ID: 30954557
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of stress-inducible HSP70 impairs mitochondrial proteostasis and function.
Leu JI; Barnoud T; Zhang G; Tian T; Wei Z; Herlyn M; Murphy ME; George DL
Oncotarget; 2017 Jul; 8(28):45656-45669. PubMed ID: 28484090
[TBL] [Abstract][Full Text] [Related]
11. Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition.
Bennett MK; Li M; Tea MN; Pitman MR; Toubia J; Wang PP; Anderson D; Creek DJ; Orlowski RZ; Gliddon BL; Powell JA; Wallington-Beddoe CT; Pitson SM
Neoplasia; 2022 Jan; 24(1):1-11. PubMed ID: 34826777
[TBL] [Abstract][Full Text] [Related]
12. DUT enhances drug resistance to proteasome inhibitors via promoting mitochondrial function in multiple myeloma.
Wang Y; Gao S; Chen L; Liu S; Ma J; Cao Z; Li Q
Carcinogenesis; 2022 Dec; 43(11):1030-1038. PubMed ID: 36426924
[TBL] [Abstract][Full Text] [Related]
13. A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment.
Chroma K; Skrott Z; Gursky J; Bacovsky J; Moudry P; Buchtova T; Mistrik M; Bartek J
Cell Death Dis; 2022 Mar; 13(3):203. PubMed ID: 35246527
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibition in multiple myeloma: lessons for other cancers.
Saavedra-García P; Martini F; Auner HW
Am J Physiol Cell Physiol; 2020 Mar; 318(3):C451-C462. PubMed ID: 31875696
[TBL] [Abstract][Full Text] [Related]
16. Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells.
Sannino S; Guerriero CJ; Sabnis AJ; Stolz DB; Wallace CT; Wipf P; Watkins SC; Bivona TG; Brodsky JL
J Cell Sci; 2018 Sep; 131(17):. PubMed ID: 30131440
[TBL] [Abstract][Full Text] [Related]
17. Deacetylation induced nuclear condensation of HP1γ promotes multiple myeloma drug resistance.
Li X; Wang S; Xie Y; Jiang H; Guo J; Wang Y; Peng Z; Hu M; Wang M; Wang J; Li Q; Wang Y; Liu Z
Nat Commun; 2023 Mar; 14(1):1290. PubMed ID: 36894562
[TBL] [Abstract][Full Text] [Related]
18. Entinostat-Bortezomib Hybrids against Multiple Myeloma.
Ferro A; Graikioti D; Gezer E; Athanassopoulos CM; Cuendet M
Molecules; 2023 Feb; 28(3):. PubMed ID: 36771118
[TBL] [Abstract][Full Text] [Related]
19. Inhibitor Combinations Reveal Wiring of the Proteostasis Network in Prostate Cancer Cells.
Shkedi A; Adkisson M; Schroeder A; Eckalbar WL; Kuo SY; Neckers L; Gestwicki JE
J Med Chem; 2021 Oct; 64(19):14809-14821. PubMed ID: 34606726
[TBL] [Abstract][Full Text] [Related]
20. A clinically relevant pulse treatment generates a bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclax.
Downey-Kopyscinski SL; Srinivasa S; Kisselev AF
Sci Rep; 2022 Jul; 12(1):12788. PubMed ID: 35896610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
